Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Nuevolution Enters Into Agreement With Howard Hughes Medical Institute, Lexicon Pharma And Duke University For Drug Discovery 11
Licensing Agreements 13
Sanofi Amends Licensing Agreement with Lexicon Pharma 13
Lexicon Pharma Expands Licensing Agreement with Ipsen 15
Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 16
Equity Offering 18
Lexicon Pharma Files Registration Statement for Public Offering of Shares 18
Lexicon Pharma Raises USD4.7 Million in Private Placement of Shares 19
Lexicon Pharma Raises USD150 Million in Private Placement of Shares 20
Lexicon Pharma Raises USD50 Million in Public Offering of Shares 22
Lexicon Pharma Completes Public Offering Of Common Stock For US$40 Million 24
Debt Offering 25
Lexicon Pharma Raises USD80 Million in Private Placement of Notes Due 2021 25
Lexicon Pharmaceuticals Inc – Key Competitors 27
Lexicon Pharmaceuticals Inc – Key Employees 28
Lexicon Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 01, 2018: Lexicon Pharmaceuticals reports third quarter 2018 financial results and provides a business update 30
Jul 30, 2018: Lexicon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides a Business Update 32
May 03, 2018: Lexicon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides a Business Update 33
Feb 22, 2018: Lexicon Pharmaceuticals Announces Fourth Quarter and Full-year 2017 Financial Results 35
Nov 08, 2017: Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides a Business Update 38
Aug 01, 2017: Lexicon Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides A Business Update 39
May 02, 2017: Lexicon Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides A Business Update 41
Mar 03, 2017: Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results 43
Product News 45
06/10/2017: Sotagliflozin Data from Pivotal inTandem1 and inTandem2 Studies in Patients with Type 1 Diabetes Presented at ADA 2017 45
06/05/2017: Lexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientific Sessions 47
03/29/2018: EMA to Review Sotagliflozin as Potential Treatment for type 1 diabetes 48
03/06/2017: Diplomat to Dispense XERMELO for Patients With Carcinoid Syndrome Diarrhea 49
03/01/2017: XERMELO (telotristat ethyl) Approved for the Treatment of Carcinoid Syndrome, Available for Order Immediately at Biologics 50
02/28/2017: FDA approves Xermelo for carcinoid syndrome diarrhea 51
Product Approvals 52
May 22, 2018: FDA to Review Zynquista (sotagliflozin) as Potential Treatment for Type 1 Diabetes 52
Mar 26, 2018: Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults with Type 1 Diabetes 53
Clinical Trials 54
Sep 13, 2017: New England Journal of Medicine Publishes Data from Phase 3 inTandem3 Study of Sotagliflozin in Patients with Type 1 Diabetes 54
Sep 08, 2017: Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 inTandem1 And inTandem2 Studies Of Sotagliflozin 56
Sep 05, 2017: Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting 57
Aug 15, 2017: Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin 58
Jun 09, 2017: Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes 60
May 11, 2017: Lexicon Pharmaceuticals Reports Additional Positive Data from Pivotal InTandem1 Phase 3 Study for Sotagliflozin in Patients with Type 1 Diabetes 61
Jan 09, 2017: Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lexicon Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nuevolution Enters Into Agreement With Howard Hughes Medical Institute, Lexicon Pharma And Duke University For Drug Discovery 11
Sanofi Amends Licensing Agreement with Lexicon Pharma 13
Lexicon Pharma Expands Licensing Agreement with Ipsen 15
Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 16
Lexicon Pharma Files Registration Statement for Public Offering of Shares 18
Lexicon Pharma Raises USD4.7 Million in Private Placement of Shares 19
Lexicon Pharma Raises USD150 Million in Private Placement of Shares 20
Lexicon Pharma Raises USD50 Million in Public Offering of Shares 22
Lexicon Pharma Completes Public Offering Of Common Stock For US$40 Million 24
Lexicon Pharma Raises USD80 Million in Private Placement of Notes Due 2021 25
Lexicon Pharmaceuticals Inc, Key Competitors 27
Lexicon Pharmaceuticals Inc, Key Employees 28
Lexicon Pharmaceuticals Inc, Subsidiaries 29
List of Figures
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9